Vendor, San Francisco, CA
Cytovale Inc.
UEI TG7HM4HD8594, CAGE 6PS42
1 award and $0 obligated between May 31, 2024 and May 7, 2025, 100% under full and open competition, against 100.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00066Definitive Contract, May 31, 2024, Full and Open Competition, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Cytovale: the Overall Objective of This Contract Is to Evaluate the Impact of the Intellisep Test on Clinical Decision-Making and Its PotentNAICS 541715, PSC AN13 | $0 |
- Places of performance
- California
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 6 across 1 awards